258.13

4.74% -12.85

After Hours: 261.80 3.67 +1.42%

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $258.13, with a volume of 597.79K. It is down -4.74% in the last 24 hours and up +53.45% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$270.98

Open:

$271

24h Volume:

597.79K

Relative Volume:

0.61

Market Cap:

$6.46B

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-28.15

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

+44.11%

1M Performance:

+53.45%

6M Performance:

+479.94%

1Y Performance:

+287.82%

1-Day Range:

$256.50

$278.44

1-Week Range:

$180.46

$278.44

52-Week Range:

$26.70

$278.44

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1131)

Industry

Biotechnology (634)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	258.13	6.78B	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	437.01	112.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	692.58	73.91B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	415.21	56.81B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	889.41	55.46B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	194.17	41.92B	447.02M	-1.18B	-906.14M	-6.1812

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Dec 09, 2025

Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - Seeking Alpha

Dec 09, 2025

PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus

Dec 09, 2025

Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative

Dec 09, 2025

Praxis Precision Medicines announces alignment with FDA - marketscreener.com

Dec 09, 2025

PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus

Dec 09, 2025

Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan

Dec 09, 2025

Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 09, 2025